Berlin, Jordan
Ramanathan, Ramesh K.
Strickler, John H.
Subramaniam, Deepa S.
Marshall, John
Kang, Yoon-Koo
Hetman, Robert
Dudley, Matthew W.
Zeng, Jiewei
Nickner, Caroline
Xiong, Hao
Komarnitsky, Philip
Shepherd, Stacie Peacock
Hurwitz, Herbert
Lenz, Heinz-Josef
Article History
Received: 29 September 2017
Revised: 20 December 2017
Accepted: 20 December 2017
First Online: 12 March 2018
Competing interests
: H.-J.L., R.K.R., and J.H.S.: research funding from AbbVie. J.B.: research funding from AbbVie and AbbVie ad board. S.P.S.: former employee of AbbVie. May hold AbbVie stock or options. Holds Abbott and Corcept stocks. D.S.S.: No disclosure pertaining to this study. Advisory board member for BMS, AstraZeneca, Takeda Oncology. H.H.: research funding from AbbVie. H.X., R.H., J.Z., P.K., C.N., and M.W.D.: employed by AbbVie. May hold AbbVie stock or options. The remaining authors declare that they have no competing financial interests.